Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6
Abstract
Mutation identification via circulating tumor DNA (ctDNA) to select appropriate therapy has demonstrated clinical utility in metastatic breast cancer (MBC). SERENA-6 demonstrated the efficacy and tolerability of camizestrant in HR + /HER2-, ESR-1 mutated MBC after an AI/CDK 4/6 inhibitor. However, it remains unclear whether switching therapy at the time of ctDNA-detected emergence of ESR-1 mutations (“molecular progression”) improves long-term outcomes over switching therapy at the time of traditional anatomic/clinical progression.
Fields of Study & Subjects
Advanced Breast Cancer Therapies
Cancer Genomics and Diagnostics
PARP inhibition in cancer therapy
Publication details
- Journal / source
- npj Breast Cancer
- Publisher
- Springer Science and Business Media LLC
- Volume
- 12
- Issue
- 1
- Pages
- 18–18
- Publication date
- 29 January 2026
- Language
- EN